NasdaqGS:SVRABiotechs
Savara (SVRA): Valuation Check After European Patent Win for MOLBREEVI in Autoimmune PAP
Savara (SVRA) just picked up a meaningful intellectual property win, with the European Patent Office signaling its intention to grant a patent on the liquid formulation of MOLBREEVI for autoimmune PAP.
See our latest analysis for Savara.
That backdrop helps explain why investors have leaned in, with the stock logging a roughly 61 percent 1 month share price return and a powerful multi year total shareholder return while momentum continues to build around MOLBREEVI.
If this kind of rare...